Intellipharmaceutics International Inc. (IPCI) Given a $6.00 Price Target at Maxim Group
Intellipharmaceutics International Inc. (NASDAQ:IPCI) received a $6.00 price objective from Maxim Group in a note issued to investors on Thursday. The brokerage currently has a a “buy” rating on the stock. Maxim Group’s price objective would indicate a potential upside of 167.74% from the company’s previous close.
Other analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Intellipharmaceutics International from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research note on Tuesday, June 21st. Brean Capital reissued a “buy” rating and issued a $8.00 price objective on shares of Intellipharmaceutics International in a research note on Tuesday, July 5th.
Intellipharmaceutics International (NASDAQ:IPCI) traded up 6.20% during trading on Thursday, reaching $2.38. The company’s stock had a trading volume of 370,868 shares. Intellipharmaceutics International has a 12 month low of $1.41 and a 12 month high of $3.19. The company’s market cap is $68.42 million. The stock’s 50-day moving average is $1.93 and its 200 day moving average is $1.83.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/intellipharmaceutics-international-inc-ipci-given-a-6-00-price-target-at-maxim-group.html
Intellipharmaceutics International (NASDAQ:IPCI) last issued its quarterly earnings data on Wednesday, July 13th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. Intellipharmaceutics International had a negative net margin of 325.20% and a negative return on equity of 832.00%. On average, equities analysts forecast that Intellipharmaceutics International will post ($0.28) EPS for the current fiscal year.
A hedge fund recently bought a new stake in Intellipharmaceutics International stock. Atria Investments LLC acquired a new stake in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) during the second quarter, according to its most recent 13F filing with the SEC. The firm acquired 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned approximately 0.27% of Intellipharmaceutics International at the end of the most recent quarter. 1.30% of the stock is owned by institutional investors.
Intellipharmaceutics International Company Profile
Intellipharmaceutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.